Table of Contents Hide
With a mission to provide effective and affordable treatments for infectious diseases, Enzolytics Inc. (OTC: ENZC) is a drug development company that has risen to prominence during the pandemic. ENZC stock has witnessed unprecedented interest from investors thanks to its ambitious mission to treat HIV and AI technology. With the company completing its 2 year audit to become SEC reporting, an uplisting to the OTCQB could be right around the corner. Meanwhile, investors are anticipating the roll out of IPF Immune through major retailers in the coming weeks as it could allow the company to report substantial financial growth. Considering that the company intends to share its growth plans in 2023, ENZC stock could be a profitable long-term hold for many investors.
ENZC Stock News
This Texas-based biotech company is concerned with the development of therapeutics which could treat a variety of diseases. Using its patented technology and proprietary methodology, ENZC has had great results in identifying sites on viruses to neutralize and treat them while protecting against mutations. However, this groundbreaking technology would not be possible without ENZC’s partner – Intel.
This major tech company facilitated ENZC’s use of artificial intelligence technology to analyze virus strains, which has now enabled its technology to predict the evolution of viruses. This means viruses and their side effects can effectively be prevented if ENZC’s technology is actionable. ENZC stated that its planning to use an AI protocol to analyze the amino acid sequences of targeted viruses in the body. The new protocol will be based on extensive analysis of existing viruses and their variants as well as new viruses as soon as they are discovered. This could later be used to develop more effective vaccines.
In October, the company announced a strategic partnership with a contract development and manufacturing company (CDMO) – Samsung Biologics. Usually pharmaceutical companies partner with CDMOs to outsource drug development and manufacturing. Because Samsung Biologics is a biotech subsidiary of Samsung Group – a world leader in contract development and manufacturing services and one of the 500 largest companies in the world – ENZC stands to benefit a lot from this partnership.
Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services for Enzelytics as part of its mission to develop and commercialize a Monoclonal Antibody Therapy for the treatment of HIV and Covid.
At the time, the COO of ENZC – Dr. Gaurav Chandra – shared that “This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic”. This indicates that Samsung’s services will not only aid in the drug’s development, but could also help with the important IND filing which is a necessary first step towards making the drug publicly available.
With a portfolio of treatments targeting Covid-19 and HIV, it’s important to first understand the cogs in the machine working behind the scenes to bring ENZC’s therapeutics to market.
The company’s primary lab is focused on the production of fully human monoclonal antibodies targeting infectious diseases such as SARS-CoV-2 and HIV-1 using ENZC’s proprietary methodology to create monoclonal antibodies that target conserved, immutable sites on the viruses.
This is potentially revolutionary work because it ensures that ENZC’s therapies are not rendered useless when viruses mutate. The methodology is already subject to pending international patent applications – giving ENZC valuable IP that will stay with the company for years to come after approval.
At its lab located at Texas A&M’s Institute for Preclinical Studies, ENZC begins the process using the proprietary A.I. platform invented by ENZC’s COO – Dr. Gaurav Chandra. The AI analyzed the structure of over 2 million Coronavirus isolates which yielded 19 target sites that are immutable and conserved across all 2 million isolates. The platform has also analyzed the HIV virus to find 8 immutable sites.
Since these sites will not change even as the virus mutates, ENZC’s next step is the production process which is used to produce monoclonal antibodies targeting the sites. During this stage, 3d models are generated of the antibodies for analysis and ENZC’s scientists use these models to produce neutralizing antibodies.
This process of producing monoclonal antibodies is unique to ENZC because it uses fully human monoclonal antibodies. Although this process is clearly one of ENZC’s assets, it is lengthy. However, the end result of processing these million cells is a single monoclonal antibody that binds to the target on the virus’ conserved site. This has allowed ENZC to target HIV-1, SARS-CoV-2, Feline Leukemia Virus (FeLV), and Feline Immunodeficiency Virus (FIV).
After producing the antibodies, they are tested for binding and neutralizing activity which is confirmed by the company’s partner labs before its CDMO partner – Samsung Biologics – produces the antibodies in its proprietary, FDA approved stable CHO cell line. Following this, ENZC will be able to conduct animal and then clinical trials.
Meanwhile, at its Dallas lab the company has been developing ITV-1 and IPF Immune which are patented under the company’s CSO – Harry Zhabilov.
ITV-1 is the therapeutic which attracted many investors to the stock because of its potential to treat HIV. The treatment already showed promising results during clinical trials conducted under the requirements of the Bulgarian Drug Agency.
While there is a long journey until commercialization, it is worth noting that the same technology is currently used to produce anti-SARS-CoV-2 antibodies for treating COVID-19. Using AI, the company is currently advancing two platforms for treating HIV. One of these platforms – ITV-1 – is already patented and clinically tested. It has previously shown significant results in HIV treatment, while the other is ENZC’s primary anti-HIV monoclonal antibody.
So far, ITV-1 has been shown to reduce HIV viral loads by 80.5%, inhibit the infection of CD4 T-cells by HIV thus raising them to healthier levels, and boost the immune system’s ability to fight HIV infections overall. The therapy can be used in combination with other anti-retroviral therapies but it’s less costly and much less toxic. On top of this it can be used periodically rather than daily and most importantly – it is unaffected by virus mutations.
In short, ITV-1 presents many advantages to anti-retroviral therapies which have serious side effects and are not able to be taken during early stages of HIV infections. This means, ITV-1 could be taken when the infection is most treatable without presenting harmful side effects. Because taking ITV-1 showed an improvement in the CD4/CD8 index, it could also be one of the few treatments available to those whose HIV infection progresses to AIDs.
Right now, ENZC is focused on completing toxicology studies after which ITV-1 would be made available in several African countries. ENZC’s subsidiary Virogentics Inc announced its progress in producing ITV-1 for the treatment of HIV patients in Central and East Africa.
ENZC intends to make this treatment available in Rwanda, the Democratic Republic of Congo, Angola, Kenya and South Africa upon the completion of these studies. At the same time, Chandra is holding talks to introduce ITV-1 for individuals in Africa. This could be a massive opportunity for ENZC given that there are 23.8 million HIV patients in Africa.
With this in mind, the company has committed to producing an initial quantity of ITV-1 for two African hospitals. Following this, the company is expected to provide larger quantities to treat about 30 thousand HIV patients.
However, ENZC will still pursue additional clinical trials to launch the therapy in the EU before seeking FDA approval. With this in mind, ENZC has brought Scandea on board to provide regulatory consulting services to reduce the time-to-market and minimize development costs.
Shareholders have held ENZC stock through thick and thin believing that its treatment is the solution for millions of people affected by HIV who are subject to expensive antiviral treatments such as Biktarvy ($42,635 per year), Dovato ($27,540 per year), and Dolutegravir/tenofovir ($48,000 per year). It’s reported that the estimated cost of care is between $1,800 to $4,500 per month for the entirety of a person’s lifetime.
In light of this, independent estimations of the projected profit from a successful HIV Monoclonal Antibody therapy sold in the seven major world markets is $105 billion over the first 11 years. However it’s important to note that prior to its EMA approval, ENZC intends to focus its treatment on Africa because of the current humanitarian issue and ITV-1’s potential to be economically supplied and produced there.
As the company leverages its technology to potentially end and even prevent future pandemics, ENZC stock has quickly become one to watch. With this in mind, ENZC’s COO Chandra is bullish that “in the next six months to one year we anticipate a monumental shift in the position of the company as our clinical products start coming to the market”.
Meanwhile, the company also signed a Letter of Intent with Creative Biolabs, Inc. for licensing and commercialization of its anti-HTLV-1 Monoclonal Antibodies back in July. As ENZC’s CEO, Charles Cotropia, said “We are now discussing licensing, commercialization, and distribution of these monoclonal antibodies with various pharmaceutical partners to expedite the development.”
But the company seems intent on diversifying after announcing its plans to enter the $50 billion dietary supplements market by producing and selling a science-backed immune modulator – Enzolytics IPF Immune.
The supplement is expected to be sold by both large and small retail outlets as well as through the IPF Immune™ website. ENZC sparked some excitement after the company launched its website for IPF Immune and made it available on Onelavi. It’s a bullish sign that the product sold out immediately on the site.
Now available in the US, IPF immune’s rollout is being facilitated by Nutritional Products International (NPI) but the supplement will also be launched in Europe and Canada. ENZC has a number of distributorship contacts in Europe which presents significant upside potential for the company once the launch is finalized.
As an immune booster, IPF strengthens the immune system against viruses as well as other pathogens without showing any side effects. Moreover, IPF Immune is able to improve recovery and reduce the recovery period after an illness. During its testing, IPF Immune showed impressive results against Covid-19 – showing similar efficacy to Tamiflu while proving to be 24 times less toxic.
Considering these results, ENZC has the potential to secure a significant market share in the $50 billion nutrition supplement market which is projected to reach $77 billion by 2028. In light of this, IPF Immune could become a major revenue stream for ENZC. Given that the company intends to share efficacy data in the upcoming weeks, ENZC stock could be one to watch for a major run.
Through its participation in ECRM’s “Weight Management, Nutrition, and Vitamin Program”, ENZC was able to introduce its supplement to several large and small retailers. While meeting with these retailers, a majority of them showed interest in IPF Immune – with 27 retailers believing the supplement was a great fit for their product lines. Based on this, ENZC expects IPF Immune to be accepted by these retailers and given the health conscious environment triggered by the pandemic, the product could continue to be met with high demand.
One of the reasons for this is the supplements’ range of applications. Helping the body fight infections, recover from disease, and more, the supplement tags viruses and disease cells allowing the body to identify threats and combat them naturally and more efficiently.
This means IPF Immune could be beneficial in therapy for oncological diseases, infectious-inflammatory diseases, pneumonia, chronic obstructive pulmonary disease, chronic bronchitis, rheumatoid arthritis. and viral diseases such as viral hepatitis, influenza, cytomegalovirus, or herpes infections.
In general, the supplement stimulates the immune system helping to cut down on the body’s recovery time by promoting antibody production and antioxidant defenses. Additionally, IPF Immune can be used in combination with other drugs to further improve treatment.
With this in mind, the initial feedback for IPF Immune was exceptional as many consumers witnessed significant improvement of their symptoms. In light of this success, many investors are bullish on ENZC stock’s future if the company is able to introduce its new supplement to various retailers such as Amazon, CVS Health, and Walgreens.
As is, the timing of its release couldn’t be better. With the supplement already launched in the US, ENZC intends to launch IPF Immune in Europe and Canada in the next three months which could have a significant impact on ENZC stock price.
Setting its therapeutics aside, an important piece of the company’s assets is its Artificial Intelligence platform which can be utilized for early drug discovery and development as well as for building up the company’s IP portfolio. Still being developed by Dr. Chandra, the platform is being built to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostics tests, all while expanding ENZC’s patent portfolio.
Already ENZC boasts a robust patent portfolio which includes patents for ITV-1 and IPF-Immune, as well as patent applications for fully human anti-HIV monoclonal antibodies and vaccines, the AI platform for use in diagnosing COVID-19 and HIV, in addition to anti-corona virus monoclonal antibodies and vaccine.
It’s important to note that, ENZC’s patent application covers the use of any one identified epitope or a combination of them for producing a therapeutic monoclonal antibody to treat HIV or Covid-19, for producing a vaccine against HIV or Covid-19, other therapeutic methods, or diagnostic tests to identify whether a person has HIV or Covid-19. These international patent applications cover all countries adhering to the Patent Cooperation Treaty
Commenting on the patent process, ENZC’s CEO shared that, “The breadth of patent coverage that is sought and expected is extremely far-reaching based on the discovery of the critical target epitope sites necessary to effectively neutralize these viruses. The Company has also identified conserved epitopes using its AI platform on multiple other viruses, […]These findings will also be protected by patent coverage.”
However, over the long-term ENZC plans to enter the personalized medicine market thanks to its unique technology. Given it’s applications, ENZC has outlined several areas of interest for the company including: genomic surveillance, monitoring of virus epidemiology, identifying conserved immutable and neutralizable sites on viruses, creating an A.I. protocol for producing monoclonal antibodies, and the human microbiome.
On this note, ENZC is also exploring applications for its AI for use in-vitro diagnostic tests which can diagnose viral diseases using conserved sites unaffected by mutations. Currently, ENZC is discussing partnering with a number of approved diagnostic companies known for distributing diagnostic tests for clinical use. Since these viruses could mutate rapidly, ENZC’s tests would not have to be modified to identify these mutations which means its tests could be universally applied.
Similarly, the possibility of using AI for prognostic tests to predict the immune response before receiving viral therapy has attracted ENZC’s attention as another route for AI driven diagnostics. Now, ENZC is negotiating with a company to develop a prognostic test that could predict immune responses before receiving a treatment or a vaccine.
By leveraging its AI platform, ENZC is able to develop drugs at a faster pace and explore new possibilities. With this in mind, ENZC’s future looks bright as the company utilizes its identified conserved epitopes and technology.
At the same time, ENZC is taking the opportunity to develop veterinarian therapies mainly for the treatment of Horse Equine Infectious Virus, Chicken Anemia Virus, Cat Feline Leukemia Virus, Feline Immunodeficiency Virus, Koala Retrovirus, and Elephant Endotheliotropic Herpes virus.
To facilitate the production of these treatments, ENZC plans to acquire patents on discovered conserved epitopes for these viruses. These patents are expected to cover the use of the discovered epitopes in producing any treatments related to these epitopes. As the global veterinarian therapeutics market is expected to grow from $31.2 billion to $54.6 billion by 2030, ENZC stock could be a promising long-term hold if it is able to secure these patents.
With ENZC’s vision expanding to include these new ventures, the company has brought in Dr. Suraj Saggar to its Advisory Board. Having conducted clinical research at the National Institute of Health, Dr. Saggar offers a wide range of expertise in diagnosing and treating infectious diseases like tuberculosis, HIV, Zika, Dengue Lyme, and SARS-CoV-2.
Currently a primary investigator in several ongoing trials of COVID-19 therapeutics and other clinical trials, Dr. Saggar’s experience is expected to aid ENZC in advancing its products to trials and patient application. Dr. Saggar will also advise the company in developing its new technologies for SARS-CoV-2 diagnostic tests and IPF Immune in addition to the company’s HIV treatment ITV-1.
*Updated June 23rd, 2022
In addition to its research for HIV and Covid-19 treatments, ENZC is determined to assist in meeting the urgent need for Monkeypox treatments. ENZC has recently identified conserved immutable sites on the virus using its technology and AI protocol for producing monoclonal antibodies. ENZC’s platform was also used to build AI-generated 3D models of all the conserved targets in the Monkeypox virus. The results of the AI analysis has already shown that all epitopes were accessible by antibodies and unaffected by mutations. Based on these findings, ENZC is confident monoclonal antibodies could become durable and unaffected by virus mutation. These findings could be pivotal pivotal since the world is already looking for a cure for the Monkeypox virus.
Between January 1st and June 15th, the WHO has recorded more than 2 thousand cases across 42 countries. Although Monkeypox is less severe than Covid-19, it could become a public health risk if the virus becomes a human pathogen and spreads to higher risk groups. In light of this, ENZC could become a pioneer in the the treatment of Monkeypox thanks to its research.
With this in mind, the US government agency CBRN Medical Countermeasures is currently exploring monoclonal antibodies for Monkeypox virus. Given that ENZC was able to discover epitopes for the virus, the company could partner with major pharma companies to develop a cure for Monkeypox.
In light of this discovery, it appears that ENZC’s AI platform is already proving its potential to eliminate future pandemics. Considering the scale of ENZC’s discovery, the company intends to apply for patents covering the identified sequences and their use in developing anti-Monkeypox monoclonal antibodies, vaccines, as well as diagnostic tests. In light of this, ENZC stock could be a smart investment over the long-term.
*Updated December 21st, 2022
Audited Financials & Future Plans
As the company is looking to drive more growth, ENZC is now one step closer to becoming fully SEC reporting after completing the audit of its 2020 and 2021 financials. In this way, ENZC is on track to deliver on its long-term goal of uplisting to the OTCQB. Now that this goal is out of the way, ENZC plans to accelerate the growth of its clinical products and technology platforms. With this in mind, ENZC is intensifying its efforts to advance the production of ITV-1 for use in Africa and EMA approval for use in Europe. At the same time, ENZC is looking to advance its AI platform technology to produce monoclonal antibodies for treating infectious diseases for humans and animals. With the company now able to focus its efforts on these endeavors, ENZC stock appears to be poised for a substantial boost in its PPS in 2023 and beyond.
On that note, ENZC promised to share plans regarding its technologies, planned partnerships, and projects, as well as its platforms’ achievements in 2023. Given that the company had major discoveries this year using its AI platform, ENZC could be well-positioned to partner with major pharma players to develop treatments for a wide range of diseases. In light of this, accumulating shares of ENZC could prove to be an extremely profitable investment in the long-term.
In other news, ENZC’s main therapeutic – IPF Immune – is now available for sale through Onelavi and the company’s IPF Immune website. ENZC is planning to roll out this product through national retailers and their online platforms and websites. With this in mind, ENZC expects IPF Immune to be available through Walmart and other major retailers in the coming weeks. In this way, ENZC could be on track to report substantial revenues in the near future.
Looking to promote its product, ENZC has been airing pre-sales promotions over the past months and has plans for future promotions and advertising. These promotions are also expected to be achieved through the platforms of retailers carrying IPF Immune. Considering that IPF Immune is set to be carried by major retailers like Walmart, the therapeutic could witness high demand – providing the company with a major revenue stream. With this in mind, additional production of IPF Immune is currently ongoing to meet the expected high demand for the therapeutic. With plans to introduce IPF Immune globally, ENZC stock could be on track for significant growth in the long-term.
ENZC Stock Financials
According to its quarterly report, ENZC has increased its total assets to $3.13 million although its cash and cash equivalents decreased with an $800 thousand investment in its subsidiaries. The company’s total liabilities amounted to $7.1 million. Administrative expenses remained low at $65 thousand along with salaries which totaled $88 thousand for the quarter. However research and development cost $555 thousand which is not unusual for a drug development company. As the company is mainly developing and testing its treatments, ENZC did not report any revenues. In short, ENZC had a net loss of $844,593 for the quarter. Despite this, ENZC could see higher revenues in the near future thanks to the successful release of IPF Immune.
ENZC Stock Forecast 2025
Revolutionizing the approach to the treatment and identification of diseases, ENZC is already gearing up to compete against Big Pharma companies. The company is working to produce antibodies for the treatment of Omicron, Small-Pox, Ebola Virus, Tetanus, and Rabies and has applied to the National Institute of Health for funding.
As such, ENZC has announced its plans to uplist to the OTCQB, stating that its application is being prepared for submission contingent on the company’s audited statements. This has led to speculations of a Big Pharma buyout.
ENZC has made exceptional progress in bringing ITV-1 to market and continues to develop this treatment with more clinical trials planned for the future. After completing its toxicology studies, ITV-1 will be made available in several African countries as the company pursues EMA approval for marketing in Europe. Considering that the treatment was already approved according to the standards of the Bulgarian Drug Agency and the added assistance Scandea brings to the table, ITV-1 appears to have a promising chance of approval. Following this, ENZC will seek FDA approval for marketing ITV-1 in the US.
Given the huge market for this treatment, any ENZC stock prediction will be reliant on ITV-1’s performance in these markets. Additionally, if the company’s patent applications are approved then ENZC stock forecast is likely bullish considering the value of these intellectual properties.
Another potential catalyst impacting the ENZC stock forecast for 2025, is the potential passage of COVID-19 research funding. In March, the Biden administration attempted to push through billions in funding as part of the $1.5 trillion omnibus spending package. While that funding was eventually cut from the legislation, there could be a renewed push for a stand-alone funding package.
On the other hand, ENZC has already brought IPF Immune to market and plans on selling the product in not just the US, but Europe and Canada as well. As the company draws on networks of distributors, the supplement may appear in more large and small retailers. This could help the company financially as it pursues its research over the next three years.
However, any long term ENZC stock forecast should consider that the company has identified conserved epitopes using its AI platform on multiple viruses. This gives the company an advantage in research and treatments related to HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).
Biotech stocks like ENZC are moved by binary events such as successful testing and FDA approval, these catalysts could push the stock further and with this in mind there are many opportunities for ENZC to bring new treatments to market through its AI platform and identified conserved epitopes.
It’s also worth noting that ENZC has not issued any additional shares since October 2020 and the company has also announced that all of its debt has flowed to its subsidiary – Robustomed, Inc. instead. Since the company is not diluting its shares, many investors believe that ENZC stock could be a profitable long-term hold.
@GodfatherCap is bullish on ENZC stock’s future prospects following its recent updates.
ENZC stock is currently trading at $.05 and has supports near .0398 and .0288. Meanwhile, the stock shows resistances near .0540 and .0751. After completing its 2 year audit, ENZC stock climbed more than 30% as the company is now on track to deliver on its promise of uplisting to the OTCQB. With the company expecting IPF Immune’s launch in Walmart and other national retailers in the coming weeks, ENZC could be one to watch closely as it could soar on more news.
Despite the significance of the company’s recent updates, ENZC failed to break through its resistance and dropped to retest its 200 MA. Since this support appears to be holding, bullish investors could wait for retests of the 200 MA to add to their positions in ENZC stock in anticipation of more updates from the company. With this in mind, a golden cross of the MAs appears to be approaching which could signal a run for ENZC.
After the stock’s recent run, accumulation took a hit which could be attributed to investors taking profits. Meanwhile, the MACD recently turned bullish following a crossover. The RSI climbed from 55 to 62 which still leaves enough room for the stock to run if more updates are released. As for its share structure, ENZC has an OS of 2.8 billion and a float of 2.3 billion.
ENZC Stock Forecast
At the moment, ENZC presents an intriguing long-term investment opportunity thanks to its potential to treat HIV and prevent the spread of several diseases. With the company now preparing to roll out IPF Immune in the US through national retailers – most notably Walmart – many investors believe that at the current ENZC stock price, the company could be undervalued.
However, ENZC’s recent completion of its 2 year audit is a major catalyst to watch as the company could become fully SEC reporting soon. In this way, ENZC appears to be on the right track to uplist to the OTCQB. Since such an uplisting would provide the company with better financing opportunities, ENZC could be poised to witness major growth in 2023 and beyond.
If you have questions about ENZC stock and where it could be heading next feel free to reach out to us in our free alerts room!
Please visit and read our disclaimer here.